Sign up USA
Proactive Investors - Run By Investors For Investors

M Pharma to pursue dual development approach with weight loss formulation

The strategy will reduce development costs and open up multiple marketing avenues addressing different market segments.
Weight loss
The OTC version will be for those who are not necessarily obese but who could do with shedding a few pounds

M Pharmaceutical Inc (CNSX:MQ) is to develop both an over-the-counter (OTC) version and a prescription version of its weight loss C-103 orlistat formulation.

Orlistat is the best-selling weight loss medication of all time.

It has a strong safety profile and is approved by the US Food & Drug Administration, but some people on the medication have experienced what can only be described in polite society as anti-social bowel-related side effects from the drug.

M Pharma’s C-103 is a combination of orlistat, simethicone (which reduces bloating) and activated charcoal, and circumvents the side-effects.

Working with its contracted partners, M will develop the foundation required to market 60 milligram (mg) OTC C-103 tablets at the same time as developing the prescription version.

The pharmaceutical company said this dual-stream approach would lower development costs.

The OTC version will be for those who have decided off their own bat, rather than on the advice of a doctor, to lose some weight.

The current plan is to have the OTC C-103 formulation available at pharmacies nationwide in the OTC format and to support it by mass marketing through multimedia channels, including both cable television and digital advertising.

"This long-term strategy will allow the company to address the larger weight loss market for those of the population that may not be technically obese but want a safe alternative to losing weight," said Gary Thompson, president and chief executive officer of M Pharmaceutical USA.

"Our strategy recognizes that we require a new branding approach for an initial national campaign, followed by the extended campaign into the global marketplace," he added.

Orlistat is approved for weight management by the US Food and Drug Administration and sold by Roche as Xenical in prescription form and by GlaxoSmithKline as alli in the OTC format.

Why Invest In M Pharmaceutical? Read More Here

Register here to be notified of future MQ Company articles
View full MQ profile

M Pharmaceutical Timeline

Related Articles

A graphic of a tumour growing in the body
July 07 2016
Nanobiotix is a late clinical-stage nanomedicine company researching novel approaches to enhance radiotherapy for the local treatment of cancer.
Concept of a DNA strand
February 14 2017
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making advances altering the inner workings of the human body to tackle deadly diseases
January 25 2017
The company's update reveals a company in rude health
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC